HD-OPM Archive
Hashtags

#rosuvastatin

24 posts

Berberine lowered plaque score 3.2% and TMAO in a small 21-patient trial

Jun 10, 2024 · Louis Nervegna ♥ 18 · 💬 23 Gut microbiome

Louis highlights a small human trial in which berberine reduced atherosclerotic plaque score, with a proposed mechanism of lowering gut-derived TMAO by acting on TMAO-producing gut bacteria. The sample is small and the comparison group was not randomized to the same degree as a large trial, so this is hypothesis-generating.

Only lipophilic statins like atorvastatin enter the brain; PCSK9 drugs and ezetimibe don't

Oct 18, 2025 · Louis Nervegna ♥ 25 · 💬 10 Brain health & dementia

Louis explains the blood-brain barrier and cholesterol: the brain makes its own cholesterol separately from blood, so non-statin LDL drugs and hydrophilic statins like rosuvastatin have little brain effect. Lipophilic statins do enter the brain, with promising observational data against Alzheimer's, and a 20,000-person atorvastatin trial is under way. Two prior trials showed statins do not worsen existing Alzheimer's, and midlife high LDL is a leading modifiable dementia risk (2024 Lancet Commission, about 7% of US cases per Louis).

Ezetimibe beyond statins: fewer events, no mortality gain in trials, registry benefits

Nov 07, 2024 · Gokhan Can ♥ 11 · 💬 22 PCSK9, ezetimibe & newer drugs

Evidence digest on ezetimibe. A meta-analysis of 15 RCTs (123,785 patients) found add-on lipid lowering cut cardiovascular events 19% versus statins alone but did not improve all-cause mortality. Other data show moderate statin plus ezetimibe matches high-intensity statins, and registry studies hint at lower mortality, with strong LDL-target attainment.

Limiting diabetes risk on LDL-lowering drugs: statin risk is modest, alternatives exist

Nov 26, 2025 · Gokhan Can ♥ 7 · 💬 17 Statins

Review explaining that statins modestly increase new-onset diabetes in a dose-dependent way, mostly in people with existing metabolic risk factors, and that cardiovascular benefit clearly outweighs this. It suggests statins mainly bring forward diagnosis in predisposed people, outlines mechanisms (beta-cell dysfunction, insulin resistance) and proposes ezetimibe, PCSK9 inhibitors and pitavastatin as options that limit glycemic harm.

Case: carotid plaque regression with salmon, niacin and low-dose rosuvastatin

Dec 23, 2023 · Louis Nervegna ♥ 13 · 💬 3 Plaque, CAC & CT angiography

Louis shares a video by Dr. Ford Brewer describing his own plaque reversal. He ate salmon daily, added niacin and low-dose rosuvastatin and switched from an ARB to an ACE inhibitor, with a major decrease in carotid plaque volume and CIMT arterial age falling from 72 to 52. It is a single self-reported case in a video from a clinic that also sells services and supplements.

Atorvastatin is generally preferred over rosuvastatin in chronic kidney disease

Dec 08, 2025 · Louis Nervegna ♥ 4 Statins

Louis shares an MRCP UK explainer on statins in CKD: atorvastatin needs no renal dose adjustment (under 2% renal excretion), while rosuvastatin is 30% renally excreted, needs dose reduction at low eGFR and can cause reversible proteinuria at high doses. KDIGO advises a statin with or without ezetimibe in CKD stages 3-5 not on dialysis.